Immunoglobulin E specific for Iva angustifolia pollen allergens (sIgE (Iva angustifolia))

Immunoglobulin E (IgE) antibodies specific for Iva angustifolia (Narrowleaf Marsh Elder) pollen allergens are the primary mediators of Type I hypersensitivity reactions in individuals sensitized to this weed (Galli & Tsai, 2012). These antibodies are produced by B cells following exposure to pollen proteins from Iva angustifolia, a plant prevalent in the South-Central United States (Pollen.com, 2025). Once formed, these specific IgE molecules bind to high-affinity FcεRI receptors on the surface of mast cells and basophils (Sandström, 2009). Subsequent exposure to the pollen allergens leads to cross-linking of the bound IgE, triggering the degranulation of these cells and the release of inflammatory mediators such as histamine and leukotrienes (Drugs.com, 2025). This process results in clinical symptoms of allergic rhinitis, conjunctivitis, and asthma (Wyndly, 2025). Therapeutic strategies targeting these antibodies include the use of omalizumab, which sequesters free IgE to prevent receptor binding, and allergen-specific immunotherapy, which aims to modulate the immune system toward a state of tolerance (NIH, 2024).

Other names

Narrowleaf marsh elder-specific IgEIva a-specific IgEAnti-Iva angustifolia IgENarrowleaf sumpweed-specific IgE

Binding and neutralization of circulating IgE to prevent its interaction with high-affinity FcεRI receptors on mast cells and basophils, thereby inhibiting the allergic cascade.